
ELENCO DELLE PRIME 15 AZIENDE FRANCESI NEL SETTORE BIOTECH

REGIONE ILE DE FRANCE

1_

LFB – Sede centrale

Laboratoire Français du Fractionnement et des Biotechnologies

3 avenue des Tropiques - BP 305 – Les Ulis

91958 Courtaboeuf Cedex – France

Telefono : **0033 1 69 82 70 10**
Fax : **0033 1 69 07 19 03**
E-mail : **communication@lfb.fr**
Sito Web : **www.lfb.fr**

Presenza in Francia

LFB Biomédicaments (Lille)

Sito produttivo a Les Ulis (91000)

Presenza all'estero

Filiale in Brasile, Germania e Regno Unito

Dati principali 2008

Fatturato (milioni di €)	352,4 (+9%)
Totale R&S (milioni di €)	70,4
Numero addetti	1531

Responsabili

Direttore :	Patrick Bougeard
Direttore Affari Generali	Guillaume Bologna

Presentazione e/o prodotti

Leader in France in the field of plasma-derived medicinal products, 6th player worldwide, LFB Group is also one of the leading European companies for the development of monoclonal antibodies and new-generation proteins based on biotechnologies.

LFB is dedicated to developing, manufacturing and marketing medicinal products for serious , and often rare diseases . R&D is key to tehe strategy of LFB Group. With a 2008 budget amounting to nearly 20% of the turnover, research projects concern both a number of developments in the field of plasma proteins,and the marketing of products based on biotechnologies, in essential therapeutic areas such as immunology, hemostasis, intensive care and oncology.

ITALIA



2_

ETHYPHARM S.A -Sede centrale
194 bureaux de la colline, Bat D
92 213 Saint-Cloud
France

Telefono : 0033 1 41 12 17 20
Fax : 0033 1 41 12 17 30
E-mail : contact@ethypharm.com
Sito web : www.ethypharm.com

Presenza in Francia :

+ 1 laboratorio a Chateauneuf en Thymerais - (28170)
+ 2 siti produttivi (Houdan -Le Grand Quevilly)- (76120)

Responsabili

Direttori Generali: Alexandre William
Guy d'Arbonneau

Dati principali 2008

Fatturato (milioni di €) 147,4
Numero addetti 550

Presenza all'estero

Ethypharm North America -200 boul. Armand-Frappier, Laval, Québec, (Canada) H7V 4A6
touam.hafid@ethypharmusa.com
Ethypharm USA Inc. -1500 Market Street, 12th Floor, East Tower - Philadelphia, PA, 19102, USA
touam.hafid@ethypharmusa.com
Ethypharm China - C-D, 11 Floor, 9 Joy Tower, No.9, Zhen Ning Road, 200051 -Shanghai, China -
hao.xiaofan@ethypharm.com.cn
Ethypharm India - Fortune 200 C1, 2nd, Bandra Kurla Complex, Bandra East, Mumbai - 400 051 -
vk Singh@ethypharmindia.com
Ethypharm Japan Shiodome Shibarikyu Bldg. 21F, 1-2-3 Kaigan, Minato-ku, Tokyo 105-0022, Japan -
ukai_keiko@ethypharm.co.jp

Prodotti

Tramadol, Oxycodone, Ketoprofen Omeprazole, Morphine Sulfate, which totalizes more than 80% market shares in France for immediate or delayed release oral forms.

Buprenorphine - The Company is also dedicated to the development of modified release oral forms of products destined for treatment of central nervous system diseases for the treatment of opiate addiction, and Mirtazapine for depression.

Ethypharm has also concentrated upon formulations and key developments in the cardiovascular field. Over 10 products are presently marketed on a world-wide scale, such as Diltiazem, ISMN or Fenofibrate.

Ethypharm recently developed Esomeprazole, a product that logically comes just after the success of the launch of its Omeprazole.

3_
HYBRIGENICS- Sede
3-5 impasse Reille
75014 Paris
France

Telefono : 0033 1 58 10 38 00
Fax : 0033 11 58 10 38 49
E-mail : contact@hybrigenics.com
Sito web : www.hybrigenics.com

Dati principali 2008

Fatturato (milioni di €)	4,2
Totale investimenti dalla data di creazione - <i>Equity fund</i> - (milioni di €)	51
Totale sovvenzioni ricevute (milioni di €)	7,4

Responsabili

Direttore : Remi Delansorne

Presenza all'estero

USA/Canada - Bioteam Boston +1 617 583 1350
Japon - CTC Laboratory System +81 (0)3 3419 9347

Presentazione e/o prodotti

Hybrigenics was founded in 1997 as a spin-off of Pasteur Institute to develop and industrialize a high throughput platform to detect and identify protein interactions using the two-hybrid technology in yeast (Yeast Two-Hybrid, Y2H).

Hybrigenics is a biotechnology and pharmaceutical company focusing its internal R&D programs on innovative target and therapeutics against cancer and commercializing its high throughput technology and bioinformatics platforms to identify, validate and inhibit protein interactions.

Hybrigenics' most advanced development program is based on inecalcitol, a vitamin D analogue, for prostate cancer in combination with current reference treatments, for improved efficacy and better tolerance. Hybrigenics' research program explores the role of Ubiquitin-Specific Proteases (USPs) in the degradation of onco-proteins, and the use of proprietary USP inhibitors against various cancer types.

Hybrigenics offers to researchers from all life sciences an access to its ISO 9001-certified Yeast-Two Hybrid (Y2H) high throughput screening platform, to its sophisticated bioinformatics set of tools and extensive database, and to its chemical library and high throughput small molecule screening platform, as fee-for-service activities.

Hybrigenics is organized in two operational units: Hybrigenics Pharma for the internal R&D programs and Hybrigenics Services for the commercial business, coordinated with economies of scale by a common corporate,

financial and administrative management. The core link among all Hybrigenics activities is trust in science for life.

_ 4

CEREP- Sede principale
155 Boulevard Haussmann
75008 Paris
France

Telefono : **0033 1 45 64 44 60**
 Fax : **0033 1 45 64 44 64**
 E-mail : **sales@cerrep.fr**
 Sito web **www.cerrep.fr**

Presenza in Francia :

+ 1 stabilimento a Poitiers (86000)

Dati principali 2008

Fatturato (milioni di €)	30,8
Totale investimenti dalla data di creazione - <i>Equity fund</i> - (milioni di €)	28,61
Totale sovvenzioni ricevute (milioni di €)	0

Responsabili

Direttore	Thierry Jean
Direttore scientifico	Olivier Gozé

Presenza all'estero

Redmond, WA (USA), Sales office in Tokyo (Japan)

Presentazione

Cerep offers preclinical drug discovery services for in vitro pharmacology, in vitro ADME-Tox & in vivo pharmacokinetics, and provides solutions allowing faster and cost-effective drug discovery by identifying at early stages the most promising drug candidates as well as eliminating those compounds likely to fail in development. Cerep has developed unique know-how based on technologies of in vitro screening and of profiling using its proprietary database BioPrint®, which allows the modeling of clinical effects of drug candidates from their molecular properties.

The strength of our services also originates from our in-house production of biological material or from established partnerships with renowned reagents providers (such as PerkinElmer). Cerep's technologies benefit to more than 460 pharmaceutical and biotechnological companies worldwide including most of the top pharmaceutical firms. Cerep's next objective is to open satellite laboratories, closer to where compounds are synthesized and drug candidates optimized, thus further decreasing turnaround time for data



generation and delivery to discovery teams. The success of this endeavour can only be achieved through the provision of consistent high quality data – reason for Cerep's permanence – wherever the screening is performed.

5 _

BIOALLIANCE PHARMA

49 bis Bd du Général Martial Val

75015 Paris

France

Telefono : **0033 1 45 58 76 00**
Fax : **0033 1 45 58 08 81**
E-mail : **bioalliance@bioalliancepharma.com**
Sito Web : **www.bioalliancepharma.com**

Dati principali 2008

Fatturato (<i>milioni di €</i>)	8,1
Addetti	91
Totale investimenti dalla data di creazione – <i>Equity fund</i> - (<i>milioni di €</i>)	104
Totale sovvenzioni ricevute (<i>milioni di €</i>)	1,5

Responsabili

Presidente : Dominique Costantini-Houist
Direttore generale Pierre Morgon

Presentazione e/o prodotti

Development of novel approaches for treating HIV and cancer.

6 _
CELLECTIS
102 avenue Gaston Roussel
93230 Romainville
France

Telefono : 0033 1 41 83 99 00
Fax : 0033 1 41 83 99 03
E-mail : mail@collectis.com
Sito Web : www.collectis.com

Dati principali 2008

Fatturato (milioni di €)	1,5
Totale investimenti dalla data di creazione - <i>Equity fund</i> - (milioni di €)	42,2
Totale sovvenzioni ricevute (milioni di €)	2,4

Responsabili

Direttore : André Choulika

Prodotti

Collectis Sa is a world leader in genome engineering. The company specializes in the development and production of meganucleases (DNA scissors) for in vivo genome surgery. Collectis products are programmed to induce unique, site-directed, double-strand DNA breaks in a living cell and can be used for a wide range of therapeutic and biotechnological applications.

7 _

EXONHIT THERAPEUTICS HYBRIGENICS**65 boulevard Masséna
75013 Paris**

Telefono : **0033 1 53 94 77 00**
Fax : **0033 1 58 05 47 19**
E-mail : **pleaseforward@exonhit.com**
Sito Web : **www.exonhit.com**

Presenza in Francia :

1 stabilimento a Pessac (33000)

Dati principali 2008

Fatturato (milioni di €)	4,2
Numero addetti	46
Totale <i>Equity fund</i> dalla data di creazione -- (milioni di €)	84,5
Totale sovvenzioni ricevute (milioni di €)	0,88

Responsabili

Direttore amministrativo: Loic Maurel
Direttore R&D: William Vickery

Presenza all'estero

ExonHit Therapeutics Inc. Avenel Business Park 217 Perry Parkway Gaithersburg, MD 20877
Tel: +1 (240) 683-7070 - Fax: +1 (240) 683-7060

Presentazione e/o prodotti

Drug discovery and diagnostics; a leader in the field of alternative RNA splicing. A strong commercial position in the microarray diagnostics and drug market.

REGIONE NORD OUEST

8_

VIVALIS

6 rue Alain Bombard
44800 Saint Herblain Cedex
Nantes - France

Telefono : 0033 2 38 07 37 10
Fax : 0033 2 28 07 37 11
E-mail : info@vivalis.com
Sito web : www.vivalis.com

Dati principali 2008

Fatturato (milioni di €)	5,4
Numero addetti	31
Totale investimenti dalla data di creazione - <i>Equity fund</i> - (milioni di €)	40
Totale sovvenzioni ricevute (milioni di €)	5

Responsabili

Presidente :	Franck Grimaud
Direttore R&D	Majid Methali

Presentazione e/o prodotti

Vivalis is a listed biopharmaceutical company that provides innovative cell-based solutions for the industrial manufacture of viral vaccines and therapeutic proteins. It is also developing vaccines and drugs for preventing and treating viral diseases.

REGIONE NORD -ESTE

9_

GENFIT**Parc Eurasanté****885 avenue Eugène Avinée****59120 Loos**

Telefono : **0033 3 20 16 40 00**
Fax : **0033 3 20 16 40 06**
E-mail : **contact@genfit.com**
Sito web : **www.genfit.com**

Dati principali 2008

Fatturato (milioni di €)	8,7
Numero addetti	125
Totale investimenti dalla data di creazione - <i>Equity fund</i> - (milioni di €)	59
Totale sovvenzioni ricevute (milioni di €)	11,3

Responsabili

Direttore Generale : Jean-François Mouney

Presenza all'estero

Genfit Corp. 245 First Street, 18 th floor – Cambridge MA 02142 (USA) – Phone + 1 (617) 444 84 16 – Fax +1 (617) 444 8405

Presentazione e/o prodotti

Genfit's research efforts are focused on the discovery and development of new treatments in the growing therapeutic areas of cardiometabolic and neurodegenerative disorders, such as prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity, and Alzheimer's.

10_

TRANSGENE

Boulevard Gonthier d'Andernach
Parc Innovation –CS 801
67405 Illkirch-Graffenstaden Cedex
France

Presenza in Francia :

+1 stabilimento a Lione (69000)

Telefono : 0033 3 88 27 91 00
Fax : 0033 3 88 22 58 07
E-mail : communication@transgene.fr
Sito web : www.transgene.fr

Dati principali 2008

Fatturato (milioni di €)	26
Numero addetti	241
Totale investimenti dalla data di creazione – <i>Equity fund</i> - (milioni di €)	310
Totale sovvenzioni ricevute (milioni di €)	4,6

Responsabili

Direttore generale: Philippe Archinard
Direttore R&D : Jean-Yves Bonnefoy

Presenza all'estero

Transgene Inc. 5510 Nicholson Lane Kensington, Maryland 20895-1078 – USA

Prodotti

Vaccini terapeutici e prodotti di immunoterapie.

REGIONE RHONE-ALPES

11_
FLAMEL TECHNOLOGIES
33 avenue du Dr. Georges Levy
69693 Venissieux Cedex France

Presenza in Francia :

+1 stabilimento a Pessac (Francia)

Telefono : **0033 4 72 78 34 34**
Fax : **0033 4 72 78 34 35**
E-mail : **info@flamel.com**
Sito web : **www.flamel.com**

Dati principali 2008

Fatturato (milioni di €) 24
Numero addetti 300
Totale investimenti dalla data
di creazione -*Equity fund* - (milioni di €)
Totale sovvenzioni ricevute (milioni di €)

Responsabili

Direttore : Stephen Willard
Direttore produzione: Raphael Jorda

Presenza all'estero

USA, Nigel McWilliam (Director, Business Development) - E-mail: mcwilliam@flamel.com

Prodotti

Medusa®, a self-assembled poly-aminoacid nanoparticle system, is a versatile protein carrier for the development of novel and second-generation long-acting native protein drugs. Medusa may also be applied other large molecules, such as monoclonal antibody fragments and peptides. The Medusa® platform has many advantages in that it enables the controlled delivery of fully-human, non-denatured proteins. We believe that this will lead to a second-generation of protein-based drugs offering greater effectiveness and reduced toxicity and

side-effects to patients. A microparticulate adaptation of Medusa has been developed that potentially can extend pharmacokinetics to two weeks or more, also without loss of bioactivity.

The Micropump® platform enables the controlled delivery of small molecule drugs that are best absorbed in the small intestine, a description that fits more than 70% of orally administered drugs. Unlike gastric-retention tablets, the Micropump® platform is well suited for applications geared towards pediatric and geriatric patients. That is because the Micropump® technology consists of the encapsulation of thousands of micro-particles, each measuring 200-500 micrometers in diameter. These microparticles can be delivered in caplets but they can also be delivered in suspensions or syrups. Because the active ingredients are entirely enclosed in each micro-particle, Micropump® offers an additional advantage of taste masking.

12_

GENOWAY

**181 Avenue Jean Jaurès
69007 Lyon - France**

Telefono : 0033 4 37 65 41 00
E-mail : info@genoway.com
Sito web : www.genoway.com

Dati principali 2008

Fatturato (milioni di €)	6,7
Numero addetti	
Totale investimenti dalla data di creazione - <i>Equity fund</i> - (milioni di €)	14,4
Totale sovvenzioni ricevute (milioni di €)	3,6

Responsabili

Direttore : **Alexandre Fraichard**

Prodotti

GenOway is a service provider dedicated to the development of genetically modified mouse and rat models.

GenOway's technology platform comprises technologies classically used in transgenesis such a pronuclear microinjection, gene knock-out, knock-in and knock-down, together with conditional and inducible systems and several innovative approaches.

REGIONE SUD-EST

13_

INNATE PHARMA - Sede**117, Avenue de Luminy – BP 30191****13009 Marseille - France**

Telefono : 0033 4 30 30 30 87
Fax : 0033 4 30 30 30 00
E-mail : business@innate-pharma.com
Sito web : www.innate-pharma.com

Dati principali 2008

Fatturato (milioni di €)	14,2
Totale investimenti dalla data di creazione – <i>Equity fund</i> - (milioni di €)	83,2
Totale sovvenzioni ricevute (milioni di €)	4,8

Responsabili

Direttore : Hervé Braille
François Magné

Presenza all'estero

Redmond, WA (USA), Sales office in Tokyo (Japan)

Prodotti

Therapeutic area, oncology, inflammation and oncology infections.

14_

IPSOGEN - Sede**163 Avenue de Luminy****13009 Marseille 09 - France**

Telefono : 0033 4 91 29 30 90
Fax : 0033 4 91 29 30 99
E-mail : infos@ipsogen.com
Sito web : www.ipsogen.com

Dati principali 2008

Fatturato (milioni di €)	3,328
Numero addetti	50
Totale investimenti dalla data di creazione - <i>Equity fund</i> - (milioni di €)	24
Totale sovvenzioni ricevute (milioni di €)	2,86

Responsabili

Direttore : Vincent Fert

Presenza all'estero

Ipsogen Inc. Stamford – Connecticut (USA)

Prodotti

Leucemia and breast cancer products.

15_
NICOX
BP 313
06906 Sophia Antipolis Cedex France

Telefono : 0033 4 97 24 53 00
Fax : 0033 4 97 24 53 09
E-mail : nicox@nicox.com
Sito web : www.nicox.com

Dati principali 2008

Fatturato (milioni di €)	3
Numero addetti	50
Totale investimenti dalla data di creazione - <i>Equity fund</i> - (milioni di €)	317,3

Responsabili

Direttore : Michele Garufi

Presenza all'estero

Nicox Research Institute Srl (Italia)
Nicox Inc. (Stati Uniti)

Prodotti

NicOx' most advanced investigational drug, naproxcinod, has successfully completed a clinical phase 3 program in patients with osteoarthritis of the knee and hip. Anti-inflammatory agents currently used in the treatment of osteoarthritis (traditional NSAIDs and COX-2 inhibitors) have long been associated with a range of side effects, including gastrointestinal problems. Furthermore, clinical findings continue to cast significant doubt on their cardiovascular safety, including their association with increased blood pressure.



Naproxcinod is a unique nitric oxide-donating anti-inflammatory compound and the first-in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide Donator) in late-phase development. NicOx aims to demonstrate that naproxcinod is an anti-inflammatory agent with no detrimental effect on blood pressure and good gastrointestinal tolerability and safety.

NicOx has completed a clinical phase 3 program for naproxcinod in patients with OA of the knee (the 301 and 302 studies) and hip (the 303 study), with all three studies achieving highly statistically significant results on all three co-primary efficacy endpoints. NicOx submitted a New Drug Application (NDA) for naproxcinod to the US Food and Drug Administration (FDA) in September 2009. NicOx received a communication in November 2009 from the FDA stating that the NDA was accepted for filing. Based on the Prescription Drug User Fee Act (PDUFA), the FDA will complete its review 10 months after submission and has set an action date of July 24, 2010. The submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) is planned for Q4 2009.